Weighing Treatment Decisions Based on Neurofilament Light Chain Levels

EP: 1.The Value of Biomarker in Multiple Sclerosis

EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis

EP: 3.Assays to Detect Neurofilament Light

EP: 4.Challenges and Opportunity With MRI

EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions

EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care

EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI

EP: 8.How to Address Increasing Neurofilament Light Chain Levels

Now Viewing

EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels

EP: 10.Monitoring Patients After a Change in Treatment Regimen

EP: 11.Assessing Lesion Types With MS Biomarkers

EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease

EP: 13.The CLIMB Study

EP: 14.Reimbursement for MRI

EP: 15.Understanding the Underlying Progression of Multiple Sclerosis

EP: 16.Biomarkers, Patient Communication, and the Future of Care

EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers

In this segment, experts discuss a scenario where a patient on a platform drug experiences a significant rise in NFL levels along with the identification of two new lesions on MRI. Ahmed Obeidat, MD, PhD, responds by stating that such a situation would trigger a conversation with the patient about potentially escalating therapy. He emphasizes the importance of considering biomarkers of neuroaxonal damage and the need for personalized treatment decisions.

They note the lack of standardized guidance on what constitutes a significant change on an MRI. He also highlights potential confounders like age, smoking, diabetes, renal disease, and pregnancy that may influence NFL levels. Tanuja Chitnis, MD, adds that other neurological diseases and comorbidities should be considered as well.

The discussion underscores the complexity of interpreting changes in NFL levels and the need to factor in various patient-specific variables and confounders. The dialogue maintains a clinical and informative tone, aligning with the user's preference for accuracy and professionalism.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.